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received TBICy. The two cohortswere comparable for patient-,
disease- and transplant-related characteristics (Table). The
sequence of TBI did not signiﬁcantly affect TRM (24% vs. 23%
@3y, p¼0.67; relative risk [RR] 1.01, p¼0.91), leukemia relapse
(27% vs. 29% @3y, p¼0.34; RR 0.89, p¼0.18), leukemia-free
survival (48% vs. 49% @3y, p¼0.27; RR 0.93, p¼0.29), chronic
graft vs. host disease (GVHD) (45%vs. 47%@1y, p¼0.39; RR0.9,
p¼ 0.11) or overall survival (53% vs. 52%@3y, p¼0.62; RR 0.96,
p¼0.57) for CyTBI and TBICy respectively. Corresponding cu-
mulative incidences of SOS were 4% and 6% @100days
(p¼0.08).While grades II-IV acute GVHD@100 dayswere 39%
vs. 45% (p¼0.01), multivariate analysis of grades II-IV acute
GVHD resulted in a RR of 0.87 (95% CI 0.75-1.00, p¼0.052).
Grades III-IV acute GVHD @100 days were 16% vs. 15%
(p¼0.62). Interaction between disease and conditioning
sequence did not show any differential effect for AML or ALL.
Conclusions: This study demonstrates that the sequence of
Cy and TBI does not impact transplant outcomes and com-
plications in patients with acute leukemia undergoing mye-
loablative transplantation. Furthermore, the results suggest
that Grades II-IV but not III-IV acute GVHD are possibly lower
with CyTBI sequence, although further evaluation is
warranted to conﬁrm this ﬁnding.14
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Aim: The composition and frequency of HLA alleles and
haplotypes vary by race/ethnic populations. Consequently, it
is thought that patients (pts) in need of an allogeneic stem
cell transplant are most likely to identify a suitably HLA
matched cell source within their own racial/ethnic group.
This study evaluated the degree of race/ethnic matching for
U.S. pts who received a transplant facilitated by Be TheMatch
Registry (BTMR).
Method: 11,870 transplants for U.S pts using a U.S donor or
cord blood unit (CBU) in BTMR database from January 2008Figure 2to October 2013 were evaluated. Pt cohort was restricted to
thosewho self identiﬁed their race/ethnicity under the broad
classiﬁcation of Black (AFA), Asian/Paciﬁc Islander (API),
White (CAU), and Hispanic (HIS). Cell source self identiﬁed
race/ethnicity were clustered into the broad race group of
AFA, API, CAU, and HIS. If the broad race/ethnicity of the pt
and source were identical the case was considered a match.
When more than one race and/or ethnicity was reported in a
pt/source they were considered race/ethnic matched if at
least one same broad race/ethnic group was reported for
both. 9243(78%) of the pts were self described as CAU with
1108 AFA, 917 HIS, and 602 API contributing 9.3%, 7.7%, and
5.1%, respectively. Comparison of race matching along with
HLA matching at transplant was also evaluated. The HLA
match was assigned a match category of x of 10 for donors
and x of 6 (antigen level HLA-A,B, allele HLA-DRB1) for CBUs
utilizing the typing provided by the transplant center.
Results: Figure 1 shows the percent of race/ethnic matching
between the pt and transplanted cell source. Greater
than 90% of CAU and HIS pt populations transplanted with a
race/ethnic matched donor or CBU, contrasted with AFA and
API pts who transplanted with race/ethnic matched CBU
less than 60% of the time. AFA and API pts showed variation
between cell sources, transplanting less often with a race/
ethnic matched CBU than donor. Further analysis of the level
of HLA match in relation to race match shows increased HLA
mismatches when the source was race/ethnic mismatched
(Figure 2). In all populations, when the source is race/ethnic.
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4/6 or worse CBUs were used. API pts were more often
transplanted with an HLA mismatched source when the
source is also race/ethnic mismatched.
Conclusion: This study shows that AFA, API, CAU, and HIS
pts, transplanted in the past 5 years, most utilized a race/
matched donor. From 2008 to present, greater than 70% of
donors and greater than 50% of CBU transplants were race/
ethnic matched between the pt and cell source. In addition,
better HLA matching was observed when the pt and cell
source were matched for race/ethnicity.15
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Haploidentical hematopoietic stem cell transplantation us-
ing T-cell depleted grafts (haploHSCT) is an option for pedi-
atric patients with high-risk hematological malignancies
lacking an HLA-identical donor. Since December 2006 to
September 2013; 55 children underwent an haploHSCT using
CD3+/CD19+ depletion for graft manipulation. Eleven pa-
tients were in 1st CR, 22 in 2nd CR and 22were in>2nd CR at
time of transplantation. The conditionig regimen consisted of
30 mg/m2/d of i.v. ﬂudarabine on days -6 to -2, 3.2-4.8 mg/
kg/day of i.v. busulfan on days -6 and -4 and 5 mg/kg/day of
i.v. thiotepa on days -3 to -2. PBPC were mobilized and
collected in the standard manner. GvHD prophylaxis
included CsA 3mg/kg/day from day -1. Allografts contained a
median of 5.75 x106 CD34 cells/kg and 1.0 x 104 CD3 cells/kg.
Median times to neutrophil and platelet recovery were 13
and 10 days, respectively. The probability of aGvHD and
cGvHD were 135% and 3110% respectively. NRM was
145% by day +100 and 216% by 2 years after transplant.
Cause of dead were relapse in 9 cases, severe viral infections
in 7 and graft failure in 2. The probability of relapse was
298%. With a median follow-up of 24 months, the proba-
bility of DFS was 558%. On a multivariate analysis the fac-
tors that positive impact on DFS were age below 12 years
(HR;0.26, 95%CI: 0.09-0.79 p<0.009) and cGvHD (HR;0.68,
95%CI: 0.01-0.53 p<0.01). Our results suggest that hap-
loidentical donors are a good option for pediatric patients
with high-risk hematological malignancies who need an
allogeneic transplantation. Graft manipulation resulted on
low incidence of severe aGvHD. DFS was better for patients
with cGvHD mainly due to lower relapse incidence. Severe
viral infections is a relevant problem in the early phase after
transplantation.16
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Background: Telomeres are long nucleotide repeats and an
associated protein complex at chromosome ends essential
for chromosomal stability. They shorten with every cell di-
vision and thus are a marker of cellular replicative capacity.
We hypothesized that telomere length may be a predictive
marker for outcomes after hematopoietic cell trans-
plantation (HCT).
Method: We used quantitative PCR (qPCR) to measure pre-
transplant relative telomere length (RTL) in blood DNA of 342
young recipients (median age¼14 yr; range¼0.5e39) and
their matched unrelated donors (median age¼36 yr;
range¼19-61). HCTs were performed for marrow failure
syndromes between 1989 and 2007 and reported to the
Center for International Blood and Marrow Transplant
Research (CIBMTR), and the National MarrowDonor Program
(NMDP). The log-rank test was used to compare survival
across RTL categories. For multivariable models, we used Cox
proportional hazard models and calculated hazard ratios
(HR) and 95% conﬁdence intervals (CI) comparing outcome
across RTL categories.
Results: Patients were followed for up to 20 years
(median¼6.3 years; range¼0.5e20.7), with an overall sur-
vival (OS) probability at 3 years of 49% (44-55). There were
243 (71%) with severe aplastic anemia, 87 (25%) with Fanconi
anemia, and 12 (4%) with Diamond Blackfan anemia. Pre-
transplant RTL in the recipients was not associated with
post-transplant outcomes, including OS (3-year survival
probability¼51% and 46%, in RTL 25% percentile and <25th
percentile-for age, respectively; p¼0.76); acute (p¼0.53 at
100 days) or chronic GVHD (p¼0.99 at 1 year) and neutrophil
engraftment (p¼0.48). Pre-transplant donor RTL was a sig-
niﬁcant predictor for OS after HCT, with longer donor telo-
mere length associated with improved survival (3 year OS
59%, 49%, and 38%, in the longest, intermediate, and shortest
tertiles, respectively; p¼0.006). No association between
donor RTL and either acute or chronic GVHD or engraftment
was observed. Donor RTL was correlated with age (R2¼0.12,
p<0.0001), but after adjusting for donor age and factors
known to inﬂuence patient survival after HCT (such as prior
treatment and time between diagnosis and transplant),
